Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01948401
Recruitment Status : Completed
First Posted : September 23, 2013
Last Update Posted : November 2, 2016
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This interventional, open study will evaluate clinical data in relation to biomarkers in patients 12 to 75 years of age with severe oral corticosteroid (OCS) - dependent asthma. Patients with uncontrolled asthma will be offered an additional escalation of OCS at a dose of 0.5 mg/kg for 7 days. Patients enrolled in this study would be eligible to be enrolled in a future placebo-controlled intervention study designed to measure the steroid-sparing effect of lebrikizumab.

Condition or disease Intervention/treatment Phase
Asthma Drug: LABA Drug: corticosteroids Drug: prednisolone Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA
Study Start Date : July 2013
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma Steroids

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Controlled asthma Drug: LABA
long-acting beta-agonist treatment

Drug: corticosteroids
chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
Experimental: Uncontrolled asthma with additional OCS Drug: LABA
long-acting beta-agonist treatment

Drug: corticosteroids
chronic treatment with oral corticosteroids, high dose inhaled corticosteroids

Drug: prednisolone
additional 0.5 mg/kg orally for 7 days
Experimental: Uncontrolled asthma without additional OCS Drug: LABA
long-acting beta-agonist treatment

Drug: corticosteroids
chronic treatment with oral corticosteroids, high dose inhaled corticosteroids


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Serum periostin levels [ Time Frame: up to 95 days ]

Secondary Outcome Measures :
  1. Asthma quality of life questionnaire for adults and adolescents aged 12 years and older (AQLQ12+) [ Time Frame: up to 95 days ]
  2. IL-13 related biomarker levels [ Time Frame: up to 95 days ]
  3. Lung function: Forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) [ Time Frame: up to 95 days ]
  4. Safety: Incidence of adverse events [ Time Frame: up to 95 days ]
  5. Patient reported outcomes: Asthma Control Questionnaire (ACQ-7) [ Time Frame: up to 95 days ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult and adolescent patients , >/=12 to </=75 years of age at the time of informed consent
  • Severe asthma (as defined by GINA step 5 classification of asthma severity) after a detailed systematic assessment (the BTS UK Difficult Asthma Network assessment model [Heaney et al 2010] or equivalent) and follow-up by an asthma specialist for at least six months
  • History of asthma treatment with high doses of inhaled corticosteroids (ICS ) (>/=1500 mcg beclomethasone dipropionate daily, or equivalent) and long-acting beta-2 agonists (LABAs), with or without an additional controller, for at least six months before Screening
  • Chronic treatment with maintenance oral corticosteroids (OCS) for at least six months before the time of informed consent ; (baseline OCS dose: adults 10 to 40 mg/day, adolescents 5 to 40 mg/day daily dose equivalent)
  • Compliance with OCS therapy will be based on prior detectable levels of serum prednisolone, cortisol suppression, or observation of Cushingoid appearance consistent with regular systemic steroid use
  • Diagnosis of refractory asthma (Heaney et al 2010) with OCS dependence on minimal effective or maximum tolerated dose
  • Confirmed (by chest x-ray) absence of other significant lung disease
  • Documented history of bronchodilator reversibility response of >/=12% and >/=200 mL within the past 12 months before the time of informed consent

Exclusion Criteria:

  • Baseline FEV1 </=39% of predicted
  • Asthma exacerbation (as defined by protocol) within 28 days before the time of informed consent or during Screening
  • Major episode of infection requiring admission to hospital for >/=24 hours or treatment with intravenous antibiotics within the 28 days before the time of informed consent or during Screening or requiring treatment with oral antibiotics within the 14 days before the time of informed consent or during Screening
  • Active parasitic infection or Listeria monocytogenes infection within the 6 months before the time of informed consent
  • For adults active tuberculosis (TB) requiring treatment within the 12 months before the time of informed consent (patients are also required to have no recurrence of symptoms in the 12 months following completion of TB treatment), or for adolescents history of active TB requiring treatment
  • Known history of severe clinically significant immunodeficiency
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • Inadequate liver function
  • Diagnosis or history of malignancy, or current investigation for possible malignancy
  • Other clinically significant medical disease that is uncontrolled despite treatment or that is likely, in the opinion of the investigator, to require a change in therapy or affect the ability to participate in the study
  • Current smoker or former smoker with a smoking history of >15 pack-years
  • Current use of an immunomodulatory/immunosuppressive therapy or past use within three months or five drug half-lives (whichever is longer) before the time of informed consent
  • Use of a biologic therapy (including omalizumab) at any time during the 4 months before the time of informed consent
  • History of anaphylaxis with omalizumab treatment or history of anaphylaxis to any therapeutic biological agent
  • Use of zileuton or roflumilast at any time during the two months before the time of informed consent
  • Initiation of or change in allergen immunotherapy within three months before the time of informed consent
  • Treatment with an investigational agent within 30 days of informed consent or 5 half-lives of the investigational agent, whichever is longer
  • Pregnant or lactating women
  • Body mass index (BMI) >38 kg/m2
  • Body weight <40 kg
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01948401


Locations
Layout table for location information
United Kingdom
Belfast, United Kingdom, BT9 7AB
Birmingham, United Kingdom, B9 5SS
Glasgow, United Kingdom, G12 0XH
Glasgow, United Kingdom, G21 3UW
Hampshire, United Kingdom, SO16 6YD
Leicester, United Kingdom, LE3 9QP
London, United Kingdom, EC1A 7BE
London, United Kingdom, SW3 6NP
Manchester, United Kingdom, M23 9LT
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Nottingham, United Kingdom, NG5 1PB
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01948401    
Other Study ID Numbers: WB28850
First Posted: September 23, 2013    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
 Prednisolone
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents